However, because diabetes induces systemic IL-17A production that has been determined to play a pivotal role in the progression of multiple diabetic complications, it would be beneficial to identify a therapeutic that could halt systemic IL-17-dependent pathology and cross the blood–retina-barrier. The gene discussed is IL17A; the disease is diabetes mellitus.